LSD1-IN-13 (compound 7e) is an orally active and potentLSD1inhibitor, with anIC₅₀of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with anEC₅₀of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines^[1].

IC₅₀: 24.43 ± 1.08 nM (LSD1), 5.00 ± 0.28 μM (LSD2), >100 μM (MAO-A), >100 μM (MAO-B)^[1]

LSD1-IN-13 (compound 7e) shows good selectivity over LSD2 (205-fold) and MAOs (>4000-fold)^[1].
LSD1-IN-13 shows potent and selective antiproliferative activity in MV-4-11, with an IC₅₀of 1.36 μM^[1].

LSD1-IN-13 (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner^[1].

411.56

C₂₃H₂₉N₃O₂S

2170212-33-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.